A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding

• Published in: Hepatology (Baltimore, Md.) Vol. 11; no. 3; p. 353
• Main Authors: Westaby, D, Polson, R J, Gimson, A E, Hayes, P C, Hayllar, K, Williams, R
• Format: Journal Article
• Language: English
• Published: United States 01.03.1990
• Subjects: Administration, Oral; Blood Pressure - drug effects; Clinical Trials as Topic; Esophageal and Gastric Varices - complications; Esophageal and Gastric Varices - drug therapy; Esophageal and Gastric Varices - therapy; Female; Follow-Up Studies; Gastrointestinal Hemorrhage - complications; Gastrointestinal Hemorrhage - drug therapy; Gastrointestinal Hemorrhage - therapy; Humans; Liver Cirrhosis - complications; Liver Cirrhosis, Alcoholic - complications; Male; Propranolol - administration & dosage; Propranolol - adverse effects; Propranolol - therapeutic use; Pulse - drug effects; Random Allocation; Recurrence; Regression Analysis; Sclerotherapy
• ISSN: 0270-9139
• DOI: 10.1002/hep.1840110304

This trial was carried out to assess the value of propranolol for the prevention of recurrent variceal bleeding in patients with well-compensated cirrhosis. We also compared propranolol therapy to long-term injection sclerotherapy. One hundred and eight patients, in whom the original variceal hemorrhage stopped spontaneously (before diagnostic endoscopy) and without sclerotherapy or surgical intervention, were included. All were Pugh grade A or B; 55% had alcoholic cirrhosis. Patients were chosen randomly to receive oral propranolol (in a dosage to reduce resting pulse rate by 25%) or to undergo long-term injection sclerotherapy. In both groups, episodes of repeat bleeding that did not stop spontaneously were managed with sclerotherapy. Patients considered to have failed propranolol therapy were treated with long-term sclerotherapy. Follow-up ranged from 12 to 64 mo. In the propranolol group, 28 (54%) of the 52 patients had repeat bleeding from varices with a total of 57 episodes; 14 received long-term sclerotherapy. In the sclerotherapy group, 25 (45%) of the 56 patients had repeat bleeding, with a total of 40 episodes (p less than 0.20). On an intention-to-treat basis, the risk of bleeding expressed per patient-month of follow-up was similar for the two groups, at 0.05 and 0.037, respectively. Survival as assessed by cumulative life analysis was also similar, with 55% and 66% alive at 3 yr (p less than 0.40). Stepwise regression analysis of possible factors predicting further bleeding in patients taking propranolol selected only two variables--the pretreatment pulse rate and the extent of pulse-rate reduction in response to propranolol.